Biocon is actively advancing in the peptide field, having already secured regulatory approvals for certain critical molecules, with a clear focus on GLP-1 analogs and other peptides
We are strengthening our market expansion through investment in manpower, regional reach and faster service turnaround to enhance application-led customer support across key industries
Country’s deep scientific talent pool and its growing role as a clinical trial destination makes it central to how Parexel serves sponsors
_256_384.jpeg)
One of our major priorities in next 3-5 years is the introduction of a kit-based version of CanAssist Breast, enabling hospitals conduct the test locally
Since 2022, we have grown threefold and our growth story is built on scale, scientific innovation and deep customer partnerships
The fast growing pharma industry in India offers us a wide range of opportunities and we represent the world's leading technology providers in india
We offer fully automated chromatography systems with customized softwares, providing customers ample time to manage R&D while the samples are being processed and results decoded
We are building the bridge between complex molecular data and everyday clinical decisions
The industry is expected to grow significantly over the next few years as healthcare accessibility improves and insurance penetration increases
We are contributing to the Indian pharmaceutical and laboratory sectors through advanced analytical instrumentation, automated liquid handling, and molecular biology solutions. Our technologies empower research and Quality Control (QC) by ensuring regulatory compliance and streamlined workflows…
Our Global Capability Center (GCC) in Bengaluru drives our major software development initiatives. Complementing this, our Bengaluru facility manufactures antibodies for research and diagnostics. Through these integrated technology and biotech operations, we are proud to contribute to India’s growth story in the life sciences sector.
Nexis GC-2060 replaces legacy baselines by introducing advanced automated workflows, expanded modularity, and enhanced detector sensitivity designed to minimize laboratory downtime
We are also acquiring company into lab equipment. We have product that meets the requirement of laboratory equipment from end to end.
Access to genomic testing, not therapy cost, is the biggest challenge
We are building an AI-native operating system for pharma sales and distribution
Enterprise-scale adoption in 2026 will be driven by domain-specific AI, compliance automation, and strong digital foundations across quality, manufacturing and regulatory workflows
While Drugs for Neglected Diseases initiative (DNDi) drives the R&D for neglected diseases, we collaborate with pharmaceutical companies at multiple stages, including sourcing promising molecules
With the convergence of AI, robotics, and neuroscience, Motorica is advancing toward more intuitive, intent-driven prosthetic systems
Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
With big pharma leaning on external pipelines, the company sees opportunity in de-risked, high-impact assets with clear clinical endpoints
Our company is prioritising deeper collaborations with CDMOs and biosimilar companies as part of its strategy to expand its footprint across India, Middle East, and Africa region
CLIRNET plans to expand globally and improve how medical knowledge is shared and used in practice
India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines
India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines
Subscribe To Our Newsletter & Stay Updated
